WO1998035653A1 - Materiau implantable de type mastic, a base de collagene - Google Patents

Materiau implantable de type mastic, a base de collagene Download PDF

Info

Publication number
WO1998035653A1
WO1998035653A1 PCT/US1998/002751 US9802751W WO9835653A1 WO 1998035653 A1 WO1998035653 A1 WO 1998035653A1 US 9802751 W US9802751 W US 9802751W WO 9835653 A1 WO9835653 A1 WO 9835653A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
collagen
composition
osteogenic
osteoinductive
Prior art date
Application number
PCT/US1998/002751
Other languages
English (en)
Inventor
Christopher J. Damien
Original Assignee
Benedict, James, A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benedict, James, A. filed Critical Benedict, James, A.
Priority to AU66545/98A priority Critical patent/AU6654598A/en
Priority to JP53591498A priority patent/JP5105216B2/ja
Priority to EP98908535A priority patent/EP1019027A4/fr
Priority to CA2280966A priority patent/CA2280966C/fr
Publication of WO1998035653A1 publication Critical patent/WO1998035653A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/102—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof

Definitions

  • the present invention relates to an implantable putty material for delivery of active compounds to a patient.
  • implantable materials have been used in the delivery of active compounds to a patient.
  • such materials can be used in the repair of bone defects.
  • these materials are implanted at a desired site to promote bone growth.
  • such a material should have the ability to adhere and conform to the implanted site and facilitate bone growth.
  • U.S. Patent Nos. 5,314,476 and 5,073,373 disclose a deformable, shape-sustaining osteogenic composition comprising demineralized bone particles and a polyhydroxy compound such as glycerol, or an oligosaccharide.
  • U.S. Patent Nos. 5,405,390 and 5,236,456 disclose a surface-adherent osteogenic composition derived from demineralized and thermally modified bone tissue.
  • the composition is administered in the form of a powder, a viscous liquid, or by direct injection.
  • U.S. Patent No. 5,246,457 discloses a bone-repair composition comprising a calcium phosphate salt and reconstituted fibrillar atelopeptide collagen. It does not include any biologically active ingredients. The physical and handling properties are improved by a number of curing processes, including heat, maturation of the wet mixture and/ specific cross-linking of collagen.
  • U.S. Patent No. 4,440,750 discloses an osteogenic composition comprising demineralized bone powder and reconstituted native atelopeptide collagen fibers in a continuous aqueous phase having a substantially physiologic pH and ionic strength.
  • U.S. Patent No. 4,975,526 discloses a matrix material comprising protein-extracted demineralized bone powder and a swelling agent to increase the intraparticle porosity of the matrix.
  • U.S. Patent No. 4,394,370 discloses a bone graft material for treating osseous defects.
  • the material comprises collagen and demineralized bone particles and is sponge-like.
  • One embodiment of the present invention is a putty material which includes collagen and water, wherein the putty material has a pH of between about 3.0 to about 6.0.
  • Materials of the invention have excellent physical properties and handling characteristics.
  • the collagen of the putty material can be selected from the group consisting of fibrillar collagen, atelopeptide collagen, telopeptide collagen and tropocollagen.
  • the putty material can be formed by the addition of an acid selected from the group consisting of ascorbic acid, acetic acid, acetyl salicylic acid, benzoic acid, citric acid, glutamic acid, glycolic acid, lactic acid, malic acid, salicylic acid, and hydrochloric acid.
  • the putty material can also include an active ingredient, such as an active ingredient selected from the group consisting of osteoinductive materials, growth factors, cartilage inducing factors, angiogenic factors, hormones, antibiotics, and antiviral compounds.
  • an active ingredient selected from the group consisting of osteoinductive materials, growth factors, cartilage inducing factors, angiogenic factors, hormones, antibiotics, and antiviral compounds.
  • Another embodiment of the present invention is an osteogenic composition which includes collagen, an osteoinductive material, and an acid, wherein the osteogenic composition includes between about 0.05 mmol of acid per 100 mg of the collagen to about 2.3 mmol of acid per 100 mg of the collagen.
  • Another embodiment of the present invention is an osteogenic composition which includes bovine tendon Type I collagen, ascorbic acid, water, bone growth protein and a demineralized bone material.
  • 7Another embodiment of the present invention is a composition produced from a process including the steps of admixing collagen, an acid, and water to form a gel; and adding a demineralized bone material to said gel to produce an ost eogenic putty, wherein the osteogenic putty has a pH of about 6.0 or less.
  • Another embodiment of the present invention is a process for making a dry osteoinductive composition comprising the steps ofadmixing collagen, an acid, an osteoinductive material and water to form a gel; and lyophilizing said gel.
  • Another embodiment of the present invention is a method for administering an active compound to a patient comprising the steps of preparing a delivery vehicle by admixing collagen and an acid to form a composition having a pH of between about 3.0 and about 6.0, incorporating an active compound into the delivery vehicle and implanting the delivery vehicle in a desired portion of the patient's body.
  • Fig. 1 illustrates volatility of ascorbic acid from an implantable material during lyophilization process.
  • Fig. 2 illustrates volatility of malic acid from an implantable material during lyophilization process.
  • Fig. 3 illustrates volatility of acetic acid from an implantable material during lyophilization process.
  • Fig. 4 illustrates volatility of lactic acid from an implantable material during lyophilization process.
  • Fig. 5 illustrates volatility of glycolic acid from an implantable material during lyophilization process.
  • the present invention is directed to a material composition which includes collagen and water.
  • the material of the present invention has a putty consistency and can be molded to a desirable shape.
  • the present invention is also directed to a process for implanting the material in the body for the purpose of stimulating or causing a biological response or activity such as inducing bone formation.
  • the material of the present invention is suitable for implanting in humans and animals with an osseous defect to induce the regeneration of osseous tissue to correct the defect.
  • the collagen component of the present invention is preferably fibrillar collagen, atelopeptide collagen, telopeptide collagen or tropocollagen and can be collected from a variety of mammalian sources.
  • the collagen is a mammalian collagen. More preferably, the collagen is selected from the group consisting of bovine Type I collagen, and porcine Type I collagen, and most preferably from the group consisting of purified fibrillar bovine tendon Type I collagen.
  • the amount of collagen present in the materials and compositions of the present invention is from about 1% by weight (not including any water that is added) to about 10% by weight, more preferably from about 2% by weight to about 8% by weight, and most preferably from about 3% by weight to about 5% by weight.
  • Materials and compositions of the present invention have a pH of between about 3 and about 6, more preferably between about 3.5 and about 5, and most preferably between about 3.8 and about 4.6.
  • the pH of the material is measured by placing a flat pH electrode on the surface of the material using Ross flat surface electrode available from Orion Co. (Boston, MA). It has been found that when the pH is within the limitations identified above, the materials have excellent physical properties, such as a putty consistency which is elastic and dough-like. At higher pH, the materials become crumbly with the consistency of wet sand. A putty consistency is desired because it provides many benefits such as enhanced cohesiveness, ease of handling and moldability. Because materials of the present invention are cohesive, they are also believed to provide the benefit of maintaining an active compound at the site of implantation longer than comparative materials with less cohesiveness.
  • a desired pH of the material of the present invention can be achieved by forming the material by adding an acid to collagen.
  • the term “acid” refers to a compound which has lower pKa than water
  • the term “acidic proton” refers to a proton whose pKa is lower than water.
  • Suitable acids for use in the present invention include organic acids, such as phenols and carboxylic acids, and inorganic acids, such as hydrochloric acid, phosphoric acid or sulfuric acid.
  • the acid is organic acid, hydrochloric acid, or phosphoric acid.
  • the acid is selected from the group consisting of acetic acid, ascorbic acid, aspartic acid, benzoic acid, citric acid, glutamic acid, glycolic acid, hydrochloric acid, lactic acid, malic acid, phosphoric acid, salicylic acid, and tartaric acid. More preferably. the acid is selected from the group consisting of ascorbic acid (i.e., vitamin C) , acetic acid, acetyl salicylic acid, benzoic acid, citric acid, glutamic acid, glycolic acid, lactic acid, malic acid, salicylic acid, and hydrochloric acid. Most preferably, the acid is selected from the group consisting of ascorbic acid, citric acid, malic acid and lactic acid.
  • the acid should be added in a sufficient amount to produce a material with acceptable physical properties.
  • the amount of acid present in the material is from about 0.05 equivalent mmole (eq. mmol) of acid per 100 mg of collagen to about 2.30 eq. mmol of acid per 100 mg of collagen, more preferably from about 0.1 eq. mmol of acid per 100 mg of collagen to about 1.5 eq. mmol of acid per 100 mg of collagen, and most preferably from about 0.2 eq. mmol of acid per 100 mg of collagen to about 1.5 eq. mmol of acid per 100 mg of collagen.
  • equivalent mmole refers to the amount of acid, in mmole, divided by the number of acidic protons present per molecule of the acid.
  • some acids such as malic acid have two equivalent acidic protons per molecule; therefore, the preferred amount of malic acid or any other acid having two acidic protons per molecule of acid is one-half that of acids having only one acidic proton.
  • 5 mmol of malic acid and 10 mmol of acetic acid can both be expressed as 10 eq. mmol of acid because malic acid has two acidic protons while acetic acid has only one acidic proton.
  • Another way to characterize the amount of acid present in the material is in terms of the amount of the acid per 100 mg of collagen.
  • the amount of the acid will vary depending on its molecular weight.
  • acid can be volatilized during lyophilization which affects the pH and the consistency of the material when the dry solid is reconstituted with water.
  • materials and compositions of the present invention have good physical properties, such as cohesiveness and retention of shape after implantation.
  • One measure of such physical properties is that materials and compositions of the present invention have a peak resistance force of at least about 10 grams (g) , preferably at least about 20 g, and more preferably at least about 30 g.
  • a “peak resistance force” refers to a maximum force exerted by the material when stretched to its breaking point using a TA.XT2 Texture Analyzer apparatus which is available from Texture Technologies Corp. (Scarsdale, New York) or some equivalent apparatus.
  • the material tested is prepared by a SMS/Kieffer molding form and press (TA-105a Texture Technologies) or some equivalent apparatus having a trapezoidal shape measuring 53 mm (1) x 4 mm (h) x 4 mm (w) at one end and 2.5 mm (w) at the other end.
  • materials and compositions of the present invention preferably have an extensibility of from about 2 mm to about 25 mm, more preferably from about 3 mm to about 25 mm, and most preferably from about 5 mm to about 25 mm.
  • extendibility refers to the distance a probe that pulls the material travels until the material breaks when using the same apparatus and the same material dimensions for testing of peak resistance force.
  • Materials of the present invention can also include an effective amount of an active ingredient.
  • An "active ingredient” refers to any compound or mixture of compounds that have a biological activity.
  • Exemplary active ingredients include osteoinductive materials, growth factors, hormones, antibiotics, and antiviral compounds. Osteoinductive materials are described in detail below.
  • Growth factors can include basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-beta) (See Cuevas et al . , Basic Fibroblast Growth Factor (FGF) Promotes Cartilage Repair In Vivo, Biochem Biophys Res Commun 156:611-618, 1988). These growth factors have been implicated as cartilage stimulating and angiogenic agents.
  • bFGF for example, has been shown to increase the rate of osteoblast replication while simultaneously inhibiting their activity ( Frenkel S, Singh IJ; The effects of fibroblast growth factor on osteogenesis in the chick embryo. In: Fundamentals of bone growth: Methodology and applications. Ed. AD Dixon, BG Sarnat, D. Hoyte, CRC Press, Boca Raton, FL, USA, pp. 245-259, 1990) . This effect is dose dependent, with higher and lower doses causing decreased activity and middle range doses stimulating activity ⁇ Aspenberg P, Thorngren KG, Lohmander LS; Dose-dependent stimulation of bone induction by basic fibroblast growth factor in rats. Acta Orthop Scand 62:481-484, 1991) .
  • the term "effective amount" refers to an amount of an active ingredient sufficient to achieve a desired affect without causing an undesirable side effect. In some cases, it may be necessary to achieve a balance between obtaining a desired effect and limiting the severity of an undesired effect. It will be appreciated that the amount of active ingredient used will vary depending upon the type of active ingredient and the intended use of the composition of the present invention.
  • the amount of osteoinductive material is preferably between about 0.1% by weight and about 10% by weight of the total weight of the putty material, more preferably between about 0.25% by weight and about 4% by weight, and most preferably between about 0.35% by weight and about 1.6% by weight.
  • osteoinductive material refers to any material that is capable of inducing bone formation (i.e., a material having osteogenic properties) when implanted in a body and includes demineralized bone matrix and osteoinductive factors.
  • osteoinductive factor refers to a natural, recombinant or synthetic protein or mixture of proteins which are capable of inducing bone formation.
  • osteoinductive factor refers to the materials described as bone growth factors in Damien et al . , U.S. Patent No. 5,563,124. It should be noted that while most contemplated applications of the present invention are concerned with use in humans, the products and processes of the present invention work in animals as well.
  • Induction of bone formation can be determined by a histological evaluation showing the de novo formation of bone with accompanying osteoblasts, osteoclasts, and osteoid matrix.
  • osteoinductive activity of an osteoinductive factor can be demonstrated by a test using a substrate onto which material to be tested is deposited. A substrate with deposited material is implanted subcutaneously in a test animal. The implant is subsequently removed and examined microscopically for the presence of bone formation including the presence of osteoblasts, osteoclasts, and osteoid matrix.
  • a suitable procedure is illustrated in Example 5 of U.S. Patent No. 5,290,763.
  • recombinantly produced osteoinductive factors refers to the production of osteoinductive factors using recombinant DNA technology.
  • nucleic acids encoding proteins having osteogenic activity can be identified by producing antibodies that bind to the proteins.
  • the antibodies can be used to isolate, by affinity chromatography, purified populations of a particular osteogenic protein.
  • the amino acid sequence can be identified by sequencing the purified protein. It is possible to synthesize DNA oligonucleotides from the known amino acid sequence.
  • the oligonucleotides can be used to screen either a genomic DNA and/or cDNA library made from, for example bovine DNA, to identify nucleic acids encoding the osteogenic protein.
  • the correct oligonucleotide will hybridize to the appropriate cDNA thereby identifying the cDNA encoding the osteogenic protein encoding gene.
  • Antibodies that bind osteogenic proteins can also be used directly to screen a cDNA expression library.
  • eukaryotic cDNA sequences encoding osteogenic proteins can be ligated into bacterial expression vectors.
  • the expression vectors can be transformed into bacteria, such as E. coli , which express the transformed expression vector and produce the osteogenic protein.
  • the transformed bacteria can be screened for expression of the osteogenic protein by lysing the bacteria and contacting the bacteria with radioactively-labelled antibody.
  • Recombinant osteoinductive factor can be produced by transfecting genes identified according to the method described above into cells using any process by which nucleic acids are inserted into cells. After transfection, the cell can produce recombinant osteoinductive factors by expression of the transfected nucleic acids and such osteoinductive factors can be recovered from the cells.
  • osteoinductive factors A number of naturally occurring proteins from bone or recombinant osteoinductive factors have been described in the literature and are suitable for the present invention.
  • Recombinantly produced osteoinductive factors have been produced by several entities.
  • Creative Biomolecules of Hopkinton, Massachusetts, USA produces a osteoinductive factor referred to as Osteogenic Protein 1 or OP1.
  • Genetics Institute of Cambridge, Massachusetts, USA produces a series of osteoinductive factors referred to as Bone Morphogenetic Proteins 1-13 (i.e., BMP 1-13), some of which are described in U.S. Patent Nos. 5,106,748 and 5,658,882 and in PCT Publication No. WO 96/39,170.
  • Purified osteoinductive factors have been developed by several entities.
  • Collagen Corporation of Palo Alto, California, USA developed a purified protein mixture which is believed to have osteogenic activity and which is described in U.S. Patent Nos. 4,774,228; 4,774,322; 4,810,691; and 4,843,063.
  • Marshall Urist of the University of California developed a purified protein mixture which is believed to be osteogenic and which is described in U.S. Patent Nos. 4,455,256; 4,619,989; 4,761,471; 4,789,732; and 4,795,804.
  • International Genetic Engineering, Inc. of Santa Monica, California, USA developed a purified protein mixture which is believed to be osteogenic and which is described in U.S. Patent No. 4,804,744. All of the foregoing patents are incorporated herein by reference.
  • a preferred osteoinductive factor of the present invention and process for making the same is described in detail in related U.S. Patent No. 5,290,763.
  • This osteoinductive factor is particularly preferred because of its high osteogenic activity and because it is a purified osteoinductive factor.
  • the osteoinductive factor of U.S. Patent No. 5,290,763 exhibits osteoinductive activity at about 3 micrograms when deposited onto a suitable carrier and implanted subcutaneously into a rat.
  • the osteoinductive factor is an osteoinductively active mixture of proteins which exhibit the gel separation profile shown in Figure 1 of U.S. Patent No. 5,563,124. This gel separation profile was obtained using SDS-PAGE.
  • the first column is a molecular weight scale which was obtained by performing SDS-PAGE on standards of known molecular weight.
  • the second column illustrates the SDS-PAGE profile for a mixture of proteins in accordance with the present invention which have been reduced with 2-mercaptoethanol.
  • the third column illustrates the SDS-PAGE profile for a non-reduced mixture of proteins in accordance with the present invention.
  • effective protein mixtures can include proteins that differ in molecular weight by plus or minus 5 KD from those shown therein, and can include fewer or greater numbers of proteins than those shown. Therefore, mixtures of proteins having profiles which comprise substantially all of the protein bands detected in the reduced or nonreduced SDS-PAGE profiles therein will be considered to be within the scope of the invention.
  • Yet another embodiment of the preferred osteoinductive factor of the invention includes an osteoinductively active mixture of proteins having, upon hydrolysis, an amino acid composition of from about 20.7 to about 26.1 mole percent acidic amino acids, about 11.3 to about 15.7 mole percent hydroxy amino acids, about 37.6 to about 42.4 mole percent aliphatic amino acids, about 5.8 to about 7.9 mole percent aromatic amino acids and about 13.3 to about 19.9 mole percent basic amino acids.
  • the preferred osteoinductive factor has an amino acid composition of about 20.7 to about 26.1 (preferably about 23.4) mole percent of ASP (+ASN) and GLU(+GLN); about 11.3 to about 15.7 (preferably about 13.5) mole percent SER and THR; about 37.6 to about 42.4 (preferably about 40.0) mole percent ALA, GLY, PRO, VAL, MET, ILE, and LEU; about 5.8 to about 7.9 (preferably about 6.8) mole percent TYR and PHE; and about 13.3 to about 19.9 (preferably about 16.6) mole percent HIS, 7ARG, and LYS .
  • a further embodiment of the preferred osteoinductive factor is a protein mixture having the approximate amino acid composition shown in Table 1.
  • a still further embodiment of the preferred osteoinductive factor is a protein mixture obtained by any of the purification processes described in U.S. Patent No. 5,290,763.
  • Materials of the present invention are typically derived by admixing collagen, water and an acid.
  • the material can also include other substances such as an active ingredient.
  • the material can also be sterilized by dialysis, irradiation (e.g. using g- radiation) , filtration, chemical treatment (e.g., using ethylene oxide), or other known sterilization methods.
  • the material which can be a gel is lyophilized to a dry solid before being sterilized.
  • a chemical treatment it is preferred that the material be lyophilized to a dry solid prior to being sterilized. Lyophilization removes water and prevents any chemical reaction which may occur between the chemical used for sterilization ( e . g. , ethylene oxide) and water.
  • Materials of the present invention can also include demineralized bone material.
  • demineralized bone material can be prepared by grinding a bone, demineralizing it with 0.6 M HC1 solution, washing with a phosphate buffered solution, washing with ethanol and drying it.
  • Demineralized bone material can also be obtained from a commercial bone or tissue bank, for example, from AlloSource (Denver, CO) .
  • kits can be part of a kit containing the components of the materials. Such kits are particularly useful for health care professionals in preparing the materials and compositions of the present invention immediately before use. Such kits, in addition to including the component parts of the various materials and compositions of the invention also include one or more containers for mixing the components, along with optional mixing devices such as stirrers. Further, such kits can include the components in sealed, pre-measured packages. The sealed packages can be sealed aseptically and the amounts of the components can be pre-measured in relative amounts as described elsewhere herein.
  • Another aspect of the present invention includes a process of implanting a material or composition as broadly described above into a body.
  • implanting refers to placing the material or composition of the present invention in an area in which it is desired to achieve the activity of the active ingredient.
  • the materials function as a delivery vehicle for an active ingredient.
  • Such methods of implantation can involve a surgery or a simple injection of the product using any of the known methods including a use of syringe.
  • the present material and process can be used in a variety of application whenever there is a need to generate bone.
  • Such applications include induction of bone formation for hip replacement operations, knee replacement operations, spinal fusion procedures, repair of periodontal defects, treatment of osteoporosis, repair of bone tumor defects, dental procedures, repair of cranialmaxillafacial defects, and repair of bone fractures.
  • the ball and socket joint of a hip is replaced when a person's hip is not functioning properly.
  • the ball portion of a joint is replaced by surgical removal of the ball portion from the terminus of the femur.
  • the artificial ball portion has a functional ball end with the opposite end being a spike which is inserted into the proximal end of the femur from which the natural ball portion was removed.
  • the spike can have a porous surface so that bone growth around the spike can anchor the spike in the femur.
  • Materials of the present invention can be layered or packed between the spike and the cavity in the femur in which spike is to be inserted.
  • the socket portion of a joint is replaced by inserting an artificial socket into the natural socket.
  • the artificial socket is sized to fit with the artificial ball.
  • the artificial socket On the surface of the artificial socket which contacts the natural socket, the artificial socket can have a porous surface. Materials of the present invention can be placed in the natural socket cavity so that upon placement of the artificial socket, the material is between the natural and artificial socket. In this manner, as bone is formed, the artificial socket is anchored in the natural socket.
  • Knee prostheses have a femoral and a tibial component which are inserted into the distal end of the femur and the surgically prepared end of the tibia, respectively.
  • Materials of the present invention can be layered or packed between the femoral and/or tibial components of the prosthesis and the respective portions of the femur and tibia. In this manner, as bone formation is induced between the prosthesis and the bones, the prosthesis becomes anchored.
  • Materials of the present invention are also suitable for use in spinal fusion operations in which it is desired to substantially immobilize two vertebrae with respect to each other.
  • the material can be applied, for example, between adjacent spinous and transverse processes so that upon bone formation throughout the material, two adjacent vertebrae are joined by fusion between the respective spinous processes and transverse processes.
  • Materials of the present inventio can also be used in spinal fusion operations in which it is desired to substantially immobilize two vertebrae with respect to each other by using metal cages or equivalent implants.
  • the cages are placed in the disk space between two vertebral bodies, and the material of the present invention is packed into and around the cages to obtain bone formation through and around the cages thus fusing two vertebrae and stabilizing the spine.
  • Bovine demineralized bone material was prepared by grinding bovine bone to a particle size of about 125 ⁇ m to about 850 ⁇ m. It was demineralized in 0.6 M HC1, washed with phosphate buffered solution, rinsed with ethanol and dried.
  • the pH of putty materials were measured using Ross flat surface electrode available from Orion Co. (Boston, MA) .
  • Example 1 This example illustrates the effect of acid on the consistency of the material produced when combined with collagen and demineralized bone material.
  • a gel was prepared by mixing 100 mg of purified bovine tendon Type I collagen and 7.4 mL of aqueous acid solution. The gel was lyophilized and then mixed with water and about 2.1 g to about 2.4 g of demineralized bone material. The resulting composition was qualitatively evaluated for its physical properties by manual examination for properties such as cohesiveness, elasticity and moldability. Each gel was graded as having acceptable physical properties or not. Some acids, such as ascorbic acid and benzoic acid, showed a wide range of useful concentrations in producing a composition having acceptable physical properties, while others such as acetic acid and lactic acid showed a narrow range of amount which is suitable for producing a composition with putty consistency. If a gel was found to initially have acceptable physical properties, it was then subjected to ethylene oxide sterilization and re-evaluated. Table 2 summarizes the qualitative evaluation of the compositions tested.
  • This example illustrates the amount of acid loss during lyophilization of compositions and the physical properties of the resulting material before and after ethylene oxide sterilization.
  • a control solution of 500 ⁇ L of a 1 M solution of the acids tested in 100 mL of water was titrated with 1 N NaOH solution.
  • samples were prepared using the procedure of Example 1, except that no demineralized bone material was added after lyophilization.
  • the resulting material was dissolved in water (at a ratio of 1 g of lyophilized material/ 100 mL) , and titrated with 1 N NaOH solution.
  • the materials, except the one made with acetic acid were subsequently treated with 2-propanol and titrated as follows.
  • This example illustrates bioactivity of the implantable materials having various acids.
  • a gel was prepared by mixing 100 mg of collagen, 7.4 mL of aqueous acid solution of a given molarity, and a given amount of bone growth protein (BGP) as described in U.S. Patent No. 5,290,763.
  • the gel was lyophilized and some of the lyophilized gels were sterilized by contacting with ethylene oxide. About 15 mg of lyophilized gel is mixed with 1.14 mL of water and 173 mg of rat demineralized bone material. The resulting material was placed in a mold and 12 to 15 disks of 7 mm diameter and 2 mm thickness was formed. The disks were frozen, lyophilized overnight, and implanted subcutaneously in rats.
  • BGP bone growth protein
  • the results showed no bone formation at 0 BGP, and at 35 ⁇ g, significantly larger amounts of bone growth occurred.
  • the results also indicate that, after ethylene oxide exposure, the osseoinductive response appears to be inversely related to the molarity of the acid. Good bone formation was observed where ascorbic acid at 30 mM and 50 mM was added to a mixture of collagen and BGP that had not been exposed to ethylene oxide, even where the ascorbic acid had itself been exposed separately to ethylene oxide. Good bone formation was observed in samples made using 10 mM and 20 mM ascorbic acid, regardless of whether it was exposed to ethylene oxide or not.
  • This example illustrates the effect of adding an acidic buffer solution to a lyophilized collagen material just prior to addition of the demineralized bone matrix.
  • a variety of acid buffer solutions including ascorbic acid at 20, 30, 50 and 100 mM, citric acid at 50 mM, malic acid at 50 mM, and lactic acid at 50 mM, can be used as an acid buffer solution in reconstituting the lyophilized collagen to obtain a material having a desired physical properties.
  • This example illustrates effect of different acids in extensibility and peak resistance force (peak force) of a material .
  • Samples for physical property testing were prepared by adding 6 mL of water to the lyophilized gel. 7 ⁇ bout 1.75 g of bovine demineralized bone material having a particle size of from 125 ⁇ m to about 850 ⁇ m was added, mixed and allowed to stand for about 5 minutes, unless otherwise noted. The putty was then placed in an SMS/Kieffer molding form and press (TA-105a Texture Technologies) . This produced test specimens having a trapozoidal shape measuring 53 mm (1) x 4 mm (h) x 4 mm (w) at one end and 2.5 mm (w) at the other end.
  • Table 5 shows a peak force and a distance to peak force measured using TA-XT2 texture analyzer with test rate (i.e., rate of probe travel) of 2.0 mm/sec and trigger force of 5.0 g for putty materials having a various acid solutions.
  • the poor result of 50 mM acetic acid sample is believed to be due to the volatility of acetic acid during lyophilization process where about 85% of the acetic acid is lost.
  • This example illustrates the effect of different acid concentration on the physical property of a putty material.
  • This example illustrates the effect of preparation time on the pH, distance to peak force and peak force of a putty material.
  • This example illustrates the effect of ethylene oxide sterilization on the physical properties of putty materials.
  • This example illustrates the changes in physical properties of putty materials due to sterilization by exposure to g-radiation.
  • Samples prepared with 50 mM or 100 mM ascorbic acid retained its putty texture even after being exposed to g- radiation.

Abstract

L'invention concerne des compositions pour matériau implantable de type mastic, qui permet d'administrer de certains composés actifs à un patient. Plus précisément, l'invention concerne un matériau dont le pH est compris entre environ 3 et 6 et qui possède les propriétés physiques caractéristiques d'un matériau de type mastic, sachant que ledit matériau renferme du collagène et de l'eau. L'invention concerne également un procédé relatif à l'utilisation de ce matériau implantable de type mastic.
PCT/US1998/002751 1997-02-13 1998-02-12 Materiau implantable de type mastic, a base de collagene WO1998035653A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU66545/98A AU6654598A (en) 1997-02-13 1998-02-12 Implantable collagen-containing putty material
JP53591498A JP5105216B2 (ja) 1997-02-13 1998-02-12 移植可能なパテ状材料
EP98908535A EP1019027A4 (fr) 1997-02-13 1998-02-12 Materiau implantable de type mastic, a base de collagene
CA2280966A CA2280966C (fr) 1997-02-13 1998-02-12 Materiau implantable de type mastic, a base de collagene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3707197P 1997-02-13 1997-02-13
US60/037,071 1997-02-13

Publications (1)

Publication Number Publication Date
WO1998035653A1 true WO1998035653A1 (fr) 1998-08-20

Family

ID=21892280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/002751 WO1998035653A1 (fr) 1997-02-13 1998-02-12 Materiau implantable de type mastic, a base de collagene

Country Status (5)

Country Link
EP (1) EP1019027A4 (fr)
JP (1) JP5105216B2 (fr)
AU (1) AU6654598A (fr)
CA (1) CA2280966C (fr)
WO (1) WO1998035653A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038163A1 (fr) * 2000-11-13 2002-05-16 El Gendler Mastic osseux et son procede
US6511958B1 (en) 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
US6514514B1 (en) 1997-08-14 2003-02-04 Sùlzer Biologics Inc. Device and method for regeneration and repair of cartilage lesions
WO2003020117A2 (fr) * 2001-08-30 2003-03-13 Gensci Orthobiologics, Inc. Compositions pour reparation tissulaire et methodes de preparation et d'utilisation associees
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6592598B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6649168B2 (en) 1999-03-17 2003-11-18 Novartis Ag Pharmaceutical compositions comprising TGF-beta
US6866668B2 (en) 1998-08-14 2005-03-15 Verigen Transplantation Service International (“VTSL”) AG Methods, instruments and materials for chondrocyte cell transplantation
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
DE102005045671A1 (de) * 2005-09-15 2007-03-29 Ossacur Ag Verwendung eines Kollagens xenogenen Ursprungs
EP2222348A2 (fr) * 2007-12-21 2010-09-01 RTI Biologics, Inc. Mastics ostéo-inducteurs et leurs procédés de fabrication et d'utilisation
US8551514B2 (en) 2004-02-23 2013-10-08 Kensey Nash Bvf Technology Llc Gel suitable for implantation and delivery system
KR101361810B1 (ko) 2011-12-22 2014-02-12 전북대학교산학협력단 조직공학용 ｄｂｐ 겔
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
US8840913B2 (en) 2008-03-27 2014-09-23 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081704A1 (en) 1998-02-13 2004-04-29 Centerpulse Biologics Inc. Implantable putty material
US20050020506A1 (en) * 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
US7824703B2 (en) * 2006-02-01 2010-11-02 Warsaw Orthopedics, Inc. Medical implants with reservoir(s), and materials preparable from same
US7892577B2 (en) * 2006-02-27 2011-02-22 Globus Medical, Inc. Bone graft materials derived from mineralized gelatin
US20070248575A1 (en) * 2006-04-19 2007-10-25 Jerome Connor Bone graft composition
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
JP2013542837A (ja) * 2010-11-15 2013-11-28 ジンマー オーソバイオロジクス，インコーポレイティド 骨空隙充填剤
KR102348476B1 (ko) * 2021-03-02 2022-01-06 한국전통문화대학교산학협력단 천연접착제 및 이의 접착강도 향상방법

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471598A (en) * 1966-02-14 1969-10-07 Fmc Corp Method of producing absorbent mats
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4066083A (en) * 1976-06-03 1978-01-03 Pentapharm A.G. Sterile surgical collagen product
US4389487A (en) * 1979-10-08 1983-06-21 Pentapharm A.G. Process for the preparation of a collagen product for medical and cosmetic purposes
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US5332802A (en) * 1988-02-18 1994-07-26 Autogenesis Technologies, Inc. Human collagen processing and autoimplant use
US5475052A (en) * 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3443261A (en) * 1967-09-01 1969-05-13 Fmc Corp Prosthetic structures from microcrystalline collagen
EP0030583B1 (fr) * 1979-12-18 1984-06-13 Oscobal Ag Matériau de remplacement des os et procédé pour sa fabrication
CA1259914A (fr) * 1984-07-06 1989-09-26 Donald G. Wallace Methodes de reparation des os a l'aide de collagene
US5707962A (en) * 1994-09-28 1998-01-13 Gensci Regeneration Sciences Inc. Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471598A (en) * 1966-02-14 1969-10-07 Fmc Corp Method of producing absorbent mats
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
US4066083A (en) * 1976-06-03 1978-01-03 Pentapharm A.G. Sterile surgical collagen product
US4389487A (en) * 1979-10-08 1983-06-21 Pentapharm A.G. Process for the preparation of a collagen product for medical and cosmetic purposes
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4440750A (en) * 1982-02-12 1984-04-03 Collagen Corporation Osteogenic composition and method
US5332802A (en) * 1988-02-18 1994-07-26 Autogenesis Technologies, Inc. Human collagen processing and autoimplant use
US5475052A (en) * 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1019027A4 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599301B2 (en) 1996-08-30 2003-07-29 Verrgen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US7048750B2 (en) 1996-08-30 2006-05-23 Verigen Ag Method, instruments, and kits for autologous transplantation
US7137989B2 (en) 1996-08-30 2006-11-21 Verigen Ag Method, instruments, and kit for autologous transplantation
US6599300B2 (en) 1996-08-30 2003-07-29 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6569172B2 (en) 1996-08-30 2003-05-27 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6592598B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6592599B2 (en) 1996-08-30 2003-07-15 Verigen Transplantation Service International (Vtsi) Method, instruments, and kit for autologous transplantation
US6514514B1 (en) 1997-08-14 2003-02-04 Sùlzer Biologics Inc. Device and method for regeneration and repair of cartilage lesions
US6511958B1 (en) 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
USRE41286E1 (en) 1997-08-14 2010-04-27 Zimmer Orthobiologics, Inc. Compositions for regeneration and repair of cartilage lesions
US6866668B2 (en) 1998-08-14 2005-03-15 Verigen Transplantation Service International (“VTSL”) AG Methods, instruments and materials for chondrocyte cell transplantation
US6649168B2 (en) 1999-03-17 2003-11-18 Novartis Ag Pharmaceutical compositions comprising TGF-beta
WO2002038163A1 (fr) * 2000-11-13 2002-05-16 El Gendler Mastic osseux et son procede
US8690874B2 (en) 2000-12-22 2014-04-08 Zimmer Orthobiologics, Inc. Composition and process for bone growth and repair
WO2003020117A3 (fr) * 2001-08-30 2004-07-01 Gensci Orthobiologics Inc Compositions pour reparation tissulaire et methodes de preparation et d'utilisation associees
US7811608B2 (en) 2001-08-30 2010-10-12 Isotis Orthobiologics, Inc. Tissue repair compositions and methods for their manufacture and use
WO2003020117A2 (fr) * 2001-08-30 2003-03-13 Gensci Orthobiologics, Inc. Compositions pour reparation tissulaire et methodes de preparation et d'utilisation associees
US7132110B2 (en) 2001-08-30 2006-11-07 Isotis Orthobiologics, Inc. Tissue repair compositions and methods for their manufacture and use
US8188229B2 (en) 2003-06-20 2012-05-29 Kensey Nash Bvf Technology, Llc High density fibrous polymers suitable for implant
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
US7214765B2 (en) 2003-06-20 2007-05-08 Kensey Nash Corporation High density fibrous polymers suitable for implant
US7910690B2 (en) 2003-06-20 2011-03-22 Kensey Nash Bvf Technology, Llc High density fibrous polymers suitable for implant
EP2305320A2 (fr) 2003-06-20 2011-04-06 Kensey Nash BVF Technology, LLC Polymers fibreux de haute densite pour implants
US11191869B2 (en) 2003-06-20 2021-12-07 Dsm Ip Assets B.V. High density fibrous polymers suitable for implant
US8633299B2 (en) 2003-06-20 2014-01-21 Kensey Nash Bvf Technology Llc High density fibrous polymers suitable for implant
US8551514B2 (en) 2004-02-23 2013-10-08 Kensey Nash Bvf Technology Llc Gel suitable for implantation and delivery system
DE102005045671A1 (de) * 2005-09-15 2007-03-29 Ossacur Ag Verwendung eines Kollagens xenogenen Ursprungs
EP2222348A2 (fr) * 2007-12-21 2010-09-01 RTI Biologics, Inc. Mastics ostéo-inducteurs et leurs procédés de fabrication et d'utilisation
US9700584B2 (en) 2007-12-21 2017-07-11 Rti Surgical, Inc. Osteoinductive putties and methods of making and using such putties
US10918670B2 (en) 2007-12-21 2021-02-16 Rti Surgical, Inc. Osteoinductive putties and methods of making and using such putties
EP2222348A4 (fr) * 2007-12-21 2011-11-23 Rti Biologics Inc Mastics ostéo-inducteurs et leurs procédés de fabrication et d'utilisation
US8840913B2 (en) 2008-03-27 2014-09-23 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
US9730982B2 (en) 2008-03-27 2017-08-15 Warsaw Orthopedic, Inc. Malleable multi-component implants and materials therefor
KR101361810B1 (ko) 2011-12-22 2014-02-12 전북대학교산학협력단 조직공학용 ｄｂｐ 겔

Also Published As

Publication number Publication date
JP5105216B2 (ja) 2012-12-26
CA2280966A1 (fr) 1998-08-20
EP1019027A1 (fr) 2000-07-19
EP1019027A4 (fr) 2004-05-12
AU6654598A (en) 1998-09-08
JP2001521414A (ja) 2001-11-06
CA2280966C (fr) 2012-04-17

Similar Documents

Publication Publication Date Title
US6679918B1 (en) Implantable putty material
US8497236B2 (en) Implantable putty material
CA2280966C (fr) Materiau implantable de type mastic, a base de collagene
CA2176205C (fr) Produit osteogene et son procede d'utilisation
AU669133B2 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
EP0837701B1 (fr) Produits osteogeniques sterilises en fin de fabrication et leur preparation
US20020082697A1 (en) Implantable osteogenic material
US5840325A (en) Osteogenic devices
EP0362367B1 (fr) Dispositifs osteogeniques
US4968590A (en) Osteogenic proteins and polypeptides
AU671721B2 (en) Tgf-beta formulation for inducing bone growth
EP1220693B1 (fr) Formulations destinees a l'administration de proteines osteogeniques
MXPA97002305A (en) Injerto formador de hu
JPH07171211A (ja) 線維芽細胞成長因子を装入した骨代替材料
JP2009101174A (ja) 多孔性β−リン酸三カルシウム顆粒および同一のものを生成する方法
EP0747067A2 (fr) Compositions de collagène moulables pour la réparation des tissus durs et augmentation
JPH10151188A (ja) 骨形成用移植体
EP1844798A1 (fr) Matériel avec mastic implantable
US20120234718A1 (en) Pharmaceutical formulation for use in spinal fusion
Geiger Porous Collagen/Ceramic Composite Carriers for Bone Regeneration Using Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)
Liu et al. Calcium sulfate Hemihydrate/Mineralized collagen for bone tissue engineering: in vitro release and in vivo bone regeneration studies
CA2223049C (fr) Produits osteogeniques sterilises en fin de fabrication et leur preparation
EP1475109A1 (fr) Formulations destinées a l'administration de protéines osteogéniques
CN101098717A (zh) 用于修复骨折的补充的基质

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2280966

Country of ref document: CA

Ref country code: JP

Ref document number: 1998 535914

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2280966

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998908535

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998908535

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998908535

Country of ref document: EP